Intercept Raises $367M As More Biotechs Pursue Follow-Ons
Liver disease treatment developer Intercept Pharmaceuticals Inc. raised about $366.8 million through a follow-on stock offering, money that the company on Monday said will fund development of its pipeline and expand...To view the full article, register now.
Already a subscriber? Click here to view full article